Leading the Future of Next Generation Sequencing

Empowering Labs.
Transforming Lives.

Our Mission

to bring precision medicine closer to every patient

We aim to broaden the reach of precision medicine by making Next Generation Sequencing (NGS) widely accessible to, and profitable for, small and medium sized labs.

Our Story

Foresee Genomics was founded on a singular belief: that cutting-edge genomic testing should be accessible to all. 

What began as a mission to dismantle barriers is now a reality, helping transform labs worldwide. From successful pilots with leading healthcare partners to scaling globally, our journey is driven by innovation and purpose—to empower labs to lead in precision medicine and deliver life-saving results faster than ever before.

Join us on our Journey
Roi Feingersch

“Every lab dreams of bringing NGS in-house, but the complexity and cost make it out of reach. I knew there had to be a better way—so I built Foresee Genomics to make that vision a reality. Now, every lab can lead in precision diagnostics.”

Roi Feingersch, Founder of Foresee Genomics

Join us on our Journey

Leadership Team

Foresee Genomics is spearheaded by experts in medical innovation and genomic diagnostics, with a proven track record in commercialization, dedicated to enhancing patient care through innovative NGS solutions.

Margalit Tocher

Margalit Tocher, MBA
CEO
Visionary leader with a proven track record in healthcare and U.S. market expansion.
Roi Feingersch

Roi Feingersch, PhD, MBA
CTO & Founder
Driving technological innovation and shaping strategic vision.
Dvir Dahary

Dvir Dahary, MSc
VP of Product Development
Expert in human clinical genetics and bioinformatics
Benjamin Cohen

Benjamin Cohen, MA
Senior Software Developer
Over ten years experience in developing breakthrough medical software solutions.
Tal Havkin-Solomon

Tal Havkin-Solomon, PhD
Senior Molecular Biologist
Experience in NGS, genome editing, protein expression, and bioinformatics.

Board of Directors

Margalit Tocher

Margalit Tocher, MBA
CEO
Visionary leader with a proven track record in healthcare and U.S. market expansion.
Roi Feingersch

Roi Feingersch, PhD, MBA
CTO & Founder
Driving technological innovation and shaping strategic vision.

Dan Shwarzman
Board Member
A seasoned global healthcare leader, with over 15 years’ healthcare experience
Eric Shapiro

Eric Shapiro
Board Member
30+ years of healthcare industry experience in marketing, operations, and M&A

Advisory Board

Yosef Maruvka

Prof. Yosef Maruvka, PhD
Assistant Professor, Cancer Genomics and Evolution,
Technion
Yosef Chait

Arnon Chait, PhD
CEO & Cofounder, ClevelandDx
Yishai Ofran

Prof. Yishai Ofran, MD
Director, Department of Hematology and Bone Marrow Transplantation, Shaare Zedek Medical Center

Copyright 2025 © Foresee Genomics | Privacy Policy | Terms of use | All rights reserved
Website created by Joya Marketing

Margalit Tocher, MBA

CEO

Visionary leader with a proven track record in healthcare and U.S. market expansion.

Ms. Tocher is the business leader of Foresee Genomics. She is a proven executive with a background in the healthcare and technology fields. Armed with an MBA in Entrepreneurship, she has successfully guided early-stage companies through transitions into successful operations with sustainable growth. Her leadership journey includes serving as CEO and COO of two thriving international medical device companies.

Linkedin-in

Roi Feingersch, PhD, MBA

CTO & Founder

Driving technological innovation and shaping strategic vision.

Dr. Feingersch is the founder of Foresee Genomics. He is an expert in the field of Next Generation Sequencing with rich experience in development of genomic diagnostic tests for cancer and genetic diseases. His experience includes developing new diagnostic tools for academic organizations, private diagnostic companies and hospitals. Dr. Feingersch is a Molecular Biologist who graduated from the Technion – Israel Institute of Technology, where he also obtained his postdoctoral fellowship.

Linkedin-in

Dvir Dahary, MSc

VP of Product Development

Expert in human clinical genetics and bioinformatics

Mr. Dahary has been working in the fields of genomics, human clinical genetics and bioinformatics for over 20 years. His experience includes leading genomic research, consulting in computational biology and specifically in the analysis of NGS data. Over the last decade, Mr. Dahary established two ventures as a co-founder and led the development of one of the first and best analysis and interpretation platforms of NGS data and clinical diagnostics – Geneyx Analysis. Mr. Dahary holds a masters degree in Cell Research and Immunology from Tel-Aviv University.

Linkedin-in

Benjamin Cohen, MA

Senior Software Developer

Over ten years experience in developing breakthrough medical software solutions.

Mr. Cohen has over ten years experience in developing software in the medical device field. Experienced in all aspects of the Software Development Life Cycle, Mr. Cohen has led multiple successful projects while maintaining compliance with applicable regulations. Whether designing a new software feature, reviewing code, or creating a Risk Analysis framework, Mr. Cohen is able to balance creativity and functionality with regulatory requirements. Mr. Cohen has a Master’s Degree in Information Systems from Northwestern University.

Linkedin-in

Dr. Tal Havkin-Solomon, PhD

Senior Molecular Biologist

Experience in NGS, genome editing, protein expression, and bioinformatics.

Dr. Havkin-Solomon is a Senior Molecular Biologist who has led innovative projects in academia and industry. She has experience in a variety of biological research systems and fields, including next-generation sequencing (NGS), genome editing, protein expression and purification, strain development, and bioinformatics. Dr. Havkin-Solomon holds a Ph.D. and a master’s degree from the Weizmann Institute of Science.

Linkedin-in

Dan Shwarzman

Board Member

A seasoned global healthcare leader, Mr. Shwarzman brings over 15 years of experience spanning Fortune 500 companies and innovative startups, driving growth and advancing medical solutions worldwide.

Mr. Shwarzman has been a leader in the global healthcare technology industry for over 15 years, with experience spanning Fortune 500 companies in the U.S. to Israeli start-ups. He is the current CEO of MindUP digital health incubator and prior to that Mr. Shwarzman was CEO and President of Virtual Ports Inc., a company developing, manufacturing and marketing innovative products to improve laparoscopic surgery. Former positions include General Manager (EndoTool Business Unit) and Director of Strategic Marketing for Hospira Worldwide, Inc., a global specialty pharmaceutical and medication delivery company, and senior positions at Johnson & Johnson (Ethicon and Ethicon EndoSurgery) and LifeWatch, Inc. He also enjoyed a 13-year career as an intelligence officer in the Israel Defense Forces.

Mr. Shwarzman holds a Master’s in Business Administration, with Honors, from the University of Chicago Booth School of Business, and a Bachelor of the Arts, Cum Laude, in Economics and Business Administration from the University of Haifa, Israel.

Linkedin-in

Eric Shapiro

Board Member

30+ years of healthcare industry experience in marketing, operations, and M&A

Mr. Shapiro is a senior executive with 30+ years of healthcare industry experience in corporate, regional and product marketing strategy and execution, operations management, as well as M&A and Corporate Development. Most recently, he was the Senior Vice President of Global Marketing at Luminex Corporation.
Linkedin-in

Prof. Yosef Maruvka, PhD

Assistant Professor, Cancer Genomics and Evolution, Technion

Prof. Yosef Maruvka earned a dual major in Physics and Math from Bar-Ilan University, followed by a Masters and PhD in physics focused on applying statistical mechanics to population genetics and evolutionary biology. He then completed a post-doctoral fellowship at the Broad Institute of MIT and Harvard where he developed methods to detect mutations in repetitive regions of the genome.

In 2020, he founded the Cancer Genomics Evolution lab at the Technion, leading a team focused on understanding early tumorigenic steps and developing methods for analyzing genomic data.

Linkedin-in

Arnon Chait, PhD

CEO & Cofounder, ClevelandDx

Driving technological innovation and shaping strategic vision.

Dr. Arnon Chait is an entrepreneur, scientist and educator who brings vast experience commercializing innovative science to his role as CEO of Cleveland Diagnostics. Arnon co-founded Cleveland Diagnostics with the Cleveland Clinic to bring early detection of cancer into everyday practice with advanced testing that is both simple and affordable.

With a background in physics, engineering and biosciences, a career spanning NASA, academia and private industry, and a history of launching and leading groundbreaking ventures with sustained revenues, Arnon has a proven track record bringing innovation to market.

He has co-invented numerous patents, has published extensively, and has developed technologies of significant impact in life sciences, from opto-electronics to novel non-invasive prenatal diagnostics—and now, novel but simple blood-based testing to make a lasting impact to benefit patients, providers, and the healthcare system.

Linkedin-in

Prof. Yishai Ofran, MD

Director, Department of Hematology and Bone Marrow Transplantation, Shaare Zedek Medical Center

Prof. Yishai Ofran is the Director of the Department of Hematology and Bone Marrow Transplantation at Shaare Zedek Medical Center. He is a leading expert in clinical molecular hematology and bone marrow transplants, with extensive experience in personalizing treatments based on molecular and genetic data. Previously, he led the leukemia service at Rambam Medical Center and directed its hematological bio-bank. His research, including pioneering work at Dana-Farber Cancer Institute, focuses on immune responses in leukemia and the development of targeted therapies.

Prof. Ofran has authored around 90 scientific publications and leads international clinical trials aimed at revolutionizing leukemia treatment. Prof. Ofran holds an MD from The Hebrew University of Jerusalem and completed his fellowship in Bone Marrow Transplantation at the Dana-Farber Cancer Institute, affiliated with Harvard University.

He is the Chairman of the Israeli Leukemia Circle and an active member of the European Society for Medical Oncology (ESMO), the European Leukemia Net (ELN), and the ECOG (Eastern Cooperative Oncology Group). In 2011, he was awarded the prestigious “Morsha” scholarship by the National Science Foundation in Israel.

Linkedin-in